Hydroxychloroquine-induced Sweet's Syndrome: A Case Report and Literature Review.

Sweet's syndrome (or acute febrile dermatosis) is a neutrophilic dermatosis with a characteristic presentation encompassing specific clinical (fever and erythemato-violaceous oedematous papules, plaques and nodules), laboratory (neutrophilia and increased inflammatory markers), and histological (dermal neutrophilic infiltrate without vasculitis) features. Its pathophysiology is poorly understood but there seems to be an auto-inflammatory component related to mutations in inflammasome genes. It has been subdivided into its classic form, malignancy-associated, and drug-induced, according to its aetiology.

Correction: Physical activity and sedentary behavior levels among individuals with mental illness: A cross-sectional study from 23 countries.

[This corrects the article DOI: 10.1371/journal.pone.

Angiogenesis Dynamics: A Computational Model of Intravascular Flow Within a Structural Adaptive Vascular Network.

Background: Understanding vascular development and the key factors involved in regulating angiogenesis-the growth of new blood vessels from pre-existing vasculature-is crucial for developing therapeutic approaches to promote wound healing. Computational techniques offer valuable insights into improving angiogenic strategies, leading to enhanced tissue regeneration and improved outcomes for chronic wound healing. While chorioallantoic membrane (CAM) models are widely used for examining fundamental mechanisms in vascular development, they lack quantification of essential parameters such as blood flow rate, intravascular pressure, and changes in vessel diameter.

First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 study.

Introduction: Renal cell carcinoma (RCC) is one of the most common types of urogenital cancer. The introduction of immune-based combinations, including dual immune-checkpoint inhibitors (ICI) or ICI plus tyrosine kinase inhibitors (TKIs), has radically changed the treatment landscape for metastatic RCC, showing varying efficacy across different prognostic groups based on the International Metastatic RCC Database Consortium (IMDC) criteria.

Materials And Methods: This retrospective multicenter study, part of the ARON-1 project, aimed to evaluate the outcomes of favorable-risk metastatic RCC patients treated with immune-based combinations or sunitinib.

Metastatic sites and clinical outcomes in renal cell carcinoma patients receiving immune-based combinations: the MOUSEION-08 study.

Immune-based combinations have significantly improved the treatment of metastatic renal cell carcinoma (mRCC); however, immunotherapy has reported varying degrees of efficacy across different metastatic sites, with liver and bone metastases traditionally considered more challenging to treat. In MOUSEION-08 study, we aimed to investigate the association between lung, liver, and bone metastases and clinical outcomes such as Overall Survival (OS) and Progression- Free Survival (PFS) in mRCC patients receiving immune-based combinations. The present systematic review and study-level meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA).